Gai Ayalon

Dr. Gai Ayalon

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
GAGai Ayalon
Gai Ayalon
SLSeung-Hye Lee
Seung-Hye Lee
OAOskar Adolfsson
Oskar Adolfsson
CFCorinne Foo-Atkins
Corinne Foo-Atkins
JAJasvinder K. Atwal
Jasvinder K. Atwal
GKGeoffrey A. Kerchner
Geoffrey A. Kerchner
Semorinemab shows beneficial effects in preclinical models and engages tau in a phase 1 study of patients with Alzheimer’s disease.

Verified
Journal Article
Open access
PDF file
ZFZhihua Feng
Zhihua Feng
SLSteven Lam
Steven Lam
ETElena-Marie Sandino Tenn
Elena-Marie Sandino Tenn
AGArundhati Sengupta Ghosh
Arundhati Sengupta Ghosh
SCSarah Cantor
Sarah Cantor
CKChien-Ping Ko
Chien-Ping Ko
Spinal muscular atrophy (SMA) is a motor neuron disease caused by insufficient levels of the survival motor neuron (SMN) protein. One of the most prominent pathological characteristics of SMA involves defects of the neuromuscular junction (NMJ), such as denervation and reduced clustering of acetylcholine receptors (AChRs). Recent studies suggest that upregulation of agrin, a crucial NMJ organizer promoting AChR clustering, can improve NMJ innervation and reduce muscle atrophy in the delta7 mouse model of SMA. To test whether the muscle-specific kinase (MuSK), part of the agrin receptor complex, also plays a beneficial role in SMA, we treated the delta7 SMA mice with an agonist antibody to MuSK. MuSK agonist antibody #13, which binds to the NMJ, significantly improved innervation and synaptic efficacy in denervation-vulnerable muscles. MuSK agonist antibody #13 also significantly increased the muscle cross-sectional area and myofiber numbers in these denervation-vulnerable muscles but not in denervation-resistant muscles. Although MuSK agonist antibody #13 did not affect the body weight, our study suggests that preservation of NMJ innervation by the activation of MuSK may serve as a complementary therapy to SMN-enhancing drugs to maximize the therapeutic effectiveness for all types of SMA patients.

26 February 2022 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
HBHanna G. Budayeva
Hanna G. Budayeva
ASArundhati Sengupta-Ghosh
Arundhati Sengupta-Ghosh
LPLilian Phu
Lilian Phu
JMJohn G. Moffat
John G. Moffat
GAGai Ayalon
Gai Ayalon
DKDonald S. Kirkpatrick
Donald S. Kirkpatrick
Muscle-specific receptor tyrosine kinase (MuSK) agonist antibodies were developed 2 decades ago to explore the benefits of receptor activation at the neuromuscular junction. Unlike agrin, the endogenous agonist of MuSK, agonist antibodies function independently of its coreceptor low-density lipoprotein receptor–related protein 4 to delay the onset of muscle denervation in mouse models of ALS. Here, we performed dose–response and time-course experiments on myotubes to systematically compare site-specific phosphorylation downstream of each agonist. Remarkably, both agonists elicited similar intracellular responses at known and newly identified MuSK signaling components. Among these was inducible tyrosine phosphorylation of multiple Rab GTPases that was blocked by MuSK inhibition. Importantly, mutation of this site in Rab10 disrupts association with its effector proteins, molecule interacting with CasL 1/3. Together, these data provide in-depth characterization of MuSK signaling, describe two novel MuSK inhibitors, and expose phosphorylation of Rab GTPases downstream of receptor tyrosine kinase activation in myotubes.

1 July 2017 in Alzheimer's & Dementia
Verified
Journal Article
Open access
KWKristin R. Wildsmith
Kristin R. Wildsmith
SBSandra Sanabria Bohorquez
Sandra Sanabria Bohorquez
PMPaul T. Manser
Paul T. Manser
KHKina Höglund
Kina Höglund
KBKaj Blennow
Kaj Blennow
RWRobby Weimer
Robby Weimer